INTS

INTENSITY THERAPEUTICS INC

3.420

-0.130-3.66%

After Hours: 3.050 -0.370 -10.82%19:30 10/14 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.560/3.550

TODAY RANGE3.293-3.580

VOL25.89K

MARKET CAP11.17M

52 WEEK RANGE3.097-43.50

AVG VOL (3M)26.80K

% TURNOVER0.76%

TURNOVER--

P/E (TTM)-0.6934

% RANGE7.63%

EPS(TTM)-4.9325

P/E(FORWARD)-1.0133

P/B1.093

BVPS3.128

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP10.73M

SHARES OUTSTANDING3.26M

NEXT EARNINGS--

FREE FLOAT3.14M

LOT SIZE1

EX-DATE02/19/2026

News

Press Releases

Financial Reports

Profile

NASDAQ·09/04 12:22
Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume
Dow Jones·08/18 17:49
Intensity Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones·08/18 17:49
Intensity Therapeutics Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
TipRanks·08/11 19:55
Intensity Therapeutics price target lowered to $15 from $30 at Alliance Global
Seeking Alpha·08/11 11:35
Intensity Therapeutics GAAP EPS of -$1.11 misses by $0.14
Dow Jones·08/11 11:31
*Intensity Therapeutics 2Q Loss/Shr $1.11 >INTS
Dow Jones·08/11 11:30
Press Release: Intensity Therapeutics Reports -3-
NASDAQ·08/04 06:22
Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress
NASDAQ·07/17 15:05
Intensity Resumes Phase 2 INVINCIBLE-4 Study For INT230-6 In Breast Cancer With Lower Dose
TipRanks·07/15 11:50
Intensity Therapeutics provides update in Invincicle-4 study
PR Newswire·07/01 12:00
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
TipRanks·06/16 21:27
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting
Seeking Alpha·05/08 10:25
Intensity Therapeutics GAAP EPS of -$0.96
PR Newswire·04/15 13:15
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
TipRanks·03/30 20:00
Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker

Same Industry

Name/Symbol

Change%

Price

INTS

Regeneron Pharmaceuticals

REGN

-1.27%

753.12

GRDX

BNTX

United Therapeutics Corp.

UTHR

+3.07%

549.16

Vertex Pharmaceuticals Inc

VRTX

+2.74%

498.50

Siga Technologie

SIGA

0.00%

3.280

Moderna

MRNA

+14.21%

225.00

CRL

Medpace Holdings

MEDP

+1.11%

616.63

TLPH

ICON plc

ICLR

+0.14%

164.40

CBPO

Iqvia Hldgs Inc

IQV

+0.92%

263.09

MOLECULAR PARTNERS AG

MOLN

+1.05%

3.850

PRAH

Gilead Sciences Inc

GILD

+2.57%

151.72

Arcturus Therape

ARCT

+6.76%

13.74

Incyte Corp

INCY

+0.04%

112.79

APVO

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.